COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes
D Focosi, M Franchini, L Pirofski… - Clinical microbiology …, 2022 - Am Soc Microbiol
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
Is SARS‐CoV‐2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody‐based therapeutics?
D Focosi, M Franchini, L Pirofski… - Reviews in Medical …, 2022 - Wiley Online Library
Viral clearance is likely the best way to assess the efficacy of antibody‐based therapies.
Although antibodies can mediate a variety of effects that include modulation of inflammation …
Although antibodies can mediate a variety of effects that include modulation of inflammation …
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
Mechanisms that could increase cancer vulnerability in COVID-19 mRNA vaccine recipients
P Azakarian - 2021 - osf.io
The BNT162b2 and mRNA-1273 vaccines have been rolled out globally in high numbers.
Even minimal risk groups have been fully vaccinated in many countries. We observe certain …
Even minimal risk groups have been fully vaccinated in many countries. We observe certain …